Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2020 | ARROW: an update on the registrational study

Mimi Hu • 21 Sep 2020
ESMO 2020
Thyroid Cancer Pralsetinib
ARROW

Mimi Hu, MD University of Texas MD Anderson Cancer Center, Houston, Texas, discusses promising results from the registrational Phase I/II ARROW trial (NCT03037385). This study investigated the safety of pralsetinib (BLU-667) in patients with advanced RET-positive mutation medullary thyroid cancer (RET+ MTC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Mimi Hu

3:06
Update on the efficacy and safety of the LIBRETTO-531 trial
Mimi Hu • 21 Sep 2020
1:26
Thyroid cancer at ESMO 2020
Mimi Hu • 21 Sep 2020

Related Videos

3:19
Future directions of targeted agents in the treatment of thyroid and neuroendocrine tumors
Enrique Grande • 22 Oct 2023
3:42
AI analysis of TILs in H&E slides to explore immune phenotypes in papillary thyroid cancer
Young Kwang Chae • 4 Jun 2023
2:10
Exploring the new frontier: radionuclide therapy in metastatic prostate cancer
Jeremie Calais • 3 Jun 2023
1:17
Evaluating the genomic landscape of thyroid cancer
Blessie Elizabeth Nelson • 17 Apr 2023
The content of VJOncology is intended for healthcare professionals